14 results about "Triamcinolone acetonide" patented technology

The invention discloses a compound nysfungin ointment, which comprises an active component, a preservative, a humectant, a thickening agent, a grease matrix and an antibacterial agent, the active component is selected from one or more of self-made mycotoxin, neomycin sulfate, permethrin and triamcinolone acetonide, the preservative is selected from benzalkonium chloride, the humectant is selected from glycerol, the thickening agent is selected from glycerol, and the grease matrix is selected from a grease matrix. The humectant is selected from humectant, the thickening agent is selected from carbomer, the grease matrix is selected from liquid paraffin and / or wool fat, the antibacterial agent is selected from thymol, and the ratio of the humectant to the thickening agent is (2-7): (0.5-3) in parts by mass. By accurately controlling the proportion of the humectant to the thickener, the texture of the ointment can be optimized, so that the skin permeability is improved, the medicine absorption is promoted, the treatment effect is improved, in addition, the form of the ointment can be kept, the active ingredients are prevented from being degraded, and the shelf life of the preparation is prolonged.

A composition and method for treating COVID-19 includes a first component including approximately 10 mg of dexamethasone and a second component including approximately 48 mg to 80 mg of triamcinolone acetonide in combination with sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80. When combined, the formulation provides dual-steroid therapy that reduces the need for tapering associated with high-dose dexamethasone, thereby minimizing adverse effects such as immunosuppression and secondary pneumonia. The composition is administered via injection and is effective for alleviating symptoms in patients with mild, moderate, or severe COVID-19 infections.

The invention discloses a drug-loaded microgel-gel sustained-release dressing as well as a preparation method and application of the drug-loaded microgel-gel sustained-release dressing. The dressing comprises a drug microgel phase loaded by GelMA microspheres and a hydrogel shell phase formed by copolymerizing CSMA and a double-bond-containing micromolecule cross-linking agent, and can be polymerized and cured in situ through ultraviolet light. The carried medicine comprises one of bevacizumab, triamcinolone acetonide and fluorouracil, and multi-medicine synergistic slow release is achieved. The dressing provided by the invention has good biocompatibility, degradability, shape adaptability and slow release performance, can significantly improve local drug concentration, reduce administration frequency and improve patient compliance, and is suitable for treatment and repair of keloid.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a compound ointment preparation for treating fungal infection and a preparation method and application thereof. According to the compound ointment preparation, chlortetracycline hydrochloride, econazole nitrate and triamcinolone acetonide compound serve as core components, no chemical incompatibility exists among chlortetracycline hydrochloride, econazole nitrate and triamcinolone acetonide, and comprehensive treatment on external auditory canal mycosis is achieved through the pharmacological synergistic effect. Meanwhile, adaptive plant essential oil is specially selected, and the proportion of active ingredients is optimized, so that the compound ointment preparation can effectively control bacteria, fungi and inflammation, the hormone amount is obviously reduced, and side effects are reduced.

A triamcinolone acetonide pharmaceutical composition and a preparation method therefor. The pharmaceutical composition contains the following ingredients: (i) a triamcinolone acetonide active ingredient, (ii) hyaluronic acid or a salt thereof. (iii) a buffering agent; and (iv) a tonicity adjustment agent. The pharmaceutical composition has a suitable viscosity, osmotic pressure and particle size range and is easily injected, especially administrated by means of a suprachoroidal space injection.

The invention relates to topical ophthalmic formulations of triamcinolone acetonide-loaded liposomes for the prevention of macular thickening and its associated visual outcomes following lens surgery. The liposome formulation comprises thermodynamically self-forming liposomes that are useful topically for treating diseases of the posterior segment of the eye.

The invention belongs to the technical field of biomedical materials, and particularly relates to a drug-loaded microneedle patch for inhibiting keloid hyperplasia and a preparation method of the drug-loaded microneedle patch. The drug-loaded microneedle patch comprises the following raw materials in parts by weight: 100 parts of an antioxidant polymer carrier, 1-5 parts of 5-fluorouracil, 0.5-3 parts of triamcinolone acetonide, 1-4 parts of a cross-linking agent and 30-60 parts of a biocompatible polymer, the antioxidant polymer carrier is composed of hyaluronic acid, ROS responsive cross-linking bridge molecules and Prussian blue nanoparticles, and the microneedle adopts a core-shell structure design. A shell layer is loaded with a quick-acting anti-proliferation drug 5-fluorouracil, a core layer is loaded with a long-acting anti-inflammatory drug triamcinolone acetonide, and the cross-linking density of the core layer is higher than that of the shell layer, so that time-divided release of the drugs is realized, and the constructed drug-loaded microneedle patch can respond to a scar microenvironment to remove excessive active oxygen and synergistically inhibit keloid hyperplasia.

The present invention relates to the technical field of organic synthesis. Disclosed is a crystal-form-controllable triamcinolone acetonide preparation method. Triamcinolone acetonide has two crystal forms, i.e. crystal form 1 and crystal form 2, respectively. The method comprises: for crystal form 1, adding ethanol to a crude product of triamcinolone acetonide for dissolution under reflux, cooling and stirring the mixture for crystallization, and performing filtering to obtain a wet product of triamcinolone acetonide; adding ethanol for dissolution under reflux, adding water to a reflux solution and controlling the temperature of the system to be 70-80ºC; and after the addition of water is complete, cooling and stirring for crystallization to obtain single crystal form 1 of triamcinolone acetonide having a low organic solvent content; and for crystal form 2, adding ethanol to a crude product of triamcinolone acetonide for dissolution under reflux, cooling and stirring the mixture for crystallization, and performing filtering to obtain a wet product of triamcinolone acetonide; adding ethanol for dissolution under reflux, cooling and stirring the mixture for crystallization to obtain single crystal form 2 of triamcinolone acetonide having a low organic solvent content. The triamcinolone acetonide preparation method of the present invention achieves crystal form controllability, high purity, and low solvent residual amount, and can prepare a product of a single crystal form according to requirements, with strong controllability, easy method production, and high process stability.

A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.

The invention relates to a triamcinolone acetonide and econazole cream for promoting barrier repair and a preparation method of the triamcinolone acetonide and econazole cream. According to the triamcinolone acetonide and econazole cream, the brown algae extract rich in fucosan is creatively introduced, so that the triamcinolone acetonide and econazole cream keeps the original anti-inflammatory and anti-fungal curative effects, meanwhile, the risks of local adverse reactions such as skin atrophy and angiotelectasis caused by triamcinolone acetonide are effectively relieved, generation of fungal drug resistance is inhibited, and the triamcinolone acetonide and econazole cream has a good application prospect. The barrier repairing and moisturizing capabilities of the skin are obviously enhanced. Besides, the red algae extract is introduced into the cream formula, and the red algae extract and the brown algae extract play a synergistic effect, so that local adverse reactions are further relieved, fungal drug resistance is inhibited, and the barrier repairing and moisturizing capacity of the skin is enhanced.

The present disclosure provides a method for manufacturing a crosslinked hyaluronic acid gel and a crosslinked hyaluronic acid gel. The crosslinked hyaluronic acid gel contains substantially evenly distributed triamcinolone.

The application provides a drug-loaded substrate, which is modified with a coating layer containing chitosan and triamcinolone acetonide. The combination of triamcinolone acetonide and chitosan in the drug-loaded substrate of the application can significantly promote the healing of the epithelial mucosa of the urinary tract and digestive tract and inhibit scar formation while inhibiting bacteria, and is a good material for preparing medical devices such as catheters.

The invention belongs to the technical field of biological medicines, and particularly relates to triamcinolone acetonide-polylactic acid sustained-release microspheres with uniform particle size as well as a preparation method and application of the triamcinolone acetonide-polylactic acid sustained-release microspheres. The triamcinolone acetonide sustained-release microsphere for injection takes triamcinolone acetonide as an effective component and polylactic acid as a carrier, and SPAN of the triamcinolone acetonide sustained-release microsphere for injection is less than or equal to 1.5. The triamcinolone acetonide sustained-release microspheres obtained by adopting the preparation method are narrower in particle size distribution, more stable in in-vitro release and small in batch difference, can pass through a very small injection needle, are more suitable for injection of subcutaneous layers, deep dermis layers and superficial dermis layers, and have wide clinical application prospects in the field of skin nodule and scar treatment.